Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gallbladder cancer: current status.

Imtiaz A Malik1

  • 1Loma Linda University Medical Center, Division of Hematology-Oncology, 11234 Anderson St, Suite 1531, Loma Linda, CA 92354, USA. imalik@ahs.llumc.edu

Expert Opinion on Pharmacotherapy
|May 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.

Cancer·2013
Same author

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.

The oncologist·2006
Same author

Use of CAM results in delay in seeking medical advice for breast cancer.

European journal of epidemiology·2003
Same author

Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases.

Journal of gastroenterology and hepatology·2003
Same author

Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.

American journal of clinical oncology·2003
Same author

Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.

American journal of clinical oncology·2003
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Gallbladder cancer (GBC) is a common biliary malignancy with poor prognosis, often diagnosed at advanced stages. Research highlights genetic factors and identifies current treatments, emphasizing surgery for early stages and chemotherapy for advanced disease.

Area of Science:

  • Oncology
  • Gastroenterology
  • Genetics

Background:

  • Gallbladder cancer (GBC) represents the most frequent biliary tract malignancy, exhibiting significant regional incidence variations.
  • Established risk factors include genetic predisposition, gender, gallstones, chronic biliary infections, dietary habits, and anatomical abnormalities.
  • Key genetic alterations like K-RAS and P53 mutations, alongside altered expression of P-glycoprotein, COX-2, and epidermal growth factor receptor, are implicated in GBC etiology and prognosis.

Purpose of the Study:

  • To review the current understanding of gallbladder cancer (GBC) epidemiology, risk factors, and genetic underpinnings.
  • To summarize the prognostic factors and current treatment strategies for GBC, including surgical and chemotherapeutic approaches.
  • To explore the potential of novel targeted therapies in managing advanced GBC.

Related Experiment Videos

Main Methods:

  • Literature review of epidemiological data, genetic studies, and clinical trials related to gallbladder cancer.
  • Analysis of prognostic indicators such as TNM staging and surgical resection extent.
  • Evaluation of current systemic chemotherapy regimens and emerging targeted therapies.

Main Results:

  • GBC incidence varies geographically, with genetic susceptibility and other factors contributing to risk.
  • Advanced stage at presentation is common, leading to a generally poor prognosis.
  • TNM stage and surgical resection extent are critical prognostic factors; surgery offers curative potential for early-stage disease.

Conclusions:

  • Current management relies on surgery for early-stage GBC and palliative chemotherapy for advanced disease, with cisplatin and gemcitabine showing promise.
  • The role of adjuvant therapy requires further definition.
  • Exploration of novel targeted therapies, potentially combined with chemotherapy, is crucial for improving outcomes in advanced GBC.